🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Ron Bose

Washington University in St. Louis

ORCID: 0000-0003-1977-8894

Also affiliated with Jewish Hospital

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 3%percentile
1.0Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer

EBioMedicine(2022)10.1016/j.ebiom.2022.104316
Top 20%
1.0DataRank
Top 20%17 citations

Lorenzo Gerratana, Katherine Clifton, Arielle J. Medford, Marko Velimirovic, Whitney L. Hensing +17 more

Papers

Driven by 11 papers — median percentile 80. Top paper: “Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial”.

Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial

Annals of Oncology(2020)10.1016/j.annonc.2020.05.012
N/A
3.1DataRank · unranked
106 citations

Sara A. Hurvitz, Jack A. Di Palma, Ron Bose, A. Jo Chien, Nicholas Iannotti +48 more

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

Annals of Oncology(2023)10.1016/j.annonc.2023.08.003
N/A
1.4DataRank · unranked
61 citations

L.D. Eli, Hans Wildiers, Sara A. Hurvitz, Ángel Guerrero‐Zotano, Nisha Unni +37 more

Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer

Breast Cancer Research and Treatment(2021)10.1007/s10549-021-06307-3
N/A
1.1DataRank · unranked
35 citations

Ina Chen, Jingqin Luo, Mothaffar F. Rimawi, Ian S. Hagemann, Bryan Fisk +29 more

Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer

EBioMedicine(2022)10.1016/j.ebiom.2022.104316
Top 20%
1.0DataRank
Top 20%17 citations

Lorenzo Gerratana, Katherine Clifton, Arielle J. Medford, Marko Velimirovic, Whitney L. Hensing +17 more

Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance

Cancer Research(2023)10.1158/0008-5472.can-22-3558
N/A
0.533DataRank · unranked
34 citations

Yirui Sun, Maureen Highkin, Nagalaxmi Vemalapally, Xiaohua Jin, Brandon Zhou +9 more

Neratinib Synergizes with Trastuzumab Antibody Drug Conjugate or with Vinorelbine to Treat HER2 Mutated Breast Cancer Patient Derived Xenografts and Organoids

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.12.19.572069
N/A
0.165DataRank · unranked
2 citations

Tina Primeau, Maureen Highkin, Stephanie L. Pratt, Ashley R. Tipton, Nagalaxmi Vemalapally +9 more

Immunogenomic Profiling and Pathological Response Results From a Clinical Trial of Docetaxel and Carboplatin in Triple Negative Breast Cancer

Research Square(2021)10.21203/rs.3.rs-420931/v1
N/A
0.104DataRank · unranked
1 citations

Ina Chen, Jingqin Luo, Mothaffar F. Rimawi, Ian S. Hagemann, Bryan Fisk +29 more

Cerebellum metastasis model of HER2-positive breast cancer unveils key role of IL34-induced Arg1+ macrophages

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.06.17.660224
N/A
0DataRank · unranked
1 citations

Khooshbu Kantibhai Patel, Brandon Zhou, Yiwei Fu, Ryan Cleary, Maureen Highkin +15 more

HER2 and APC Mutations Promote Altered Crypt-Villus Morphology and Marked Hyperplasia in the Intestinal Epithelium

Cellular and Molecular Gastroenterology and Hepatology(2021)10.1016/j.jcmgh.2021.04.012
N/A
0DataRank · unranked
11 citations

Xiaoqing Cheng, Anagha Krishna, Xiaohua Jin, Takahiro E. Ohara, Thaddeus S. Stappenbeck +2 more

Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.11.09.515796
N/A
0DataRank · unranked
0 citations

Yirui Sun, Maureen Highkin, Nagalaxmi Vemalapally, Xiaohua Jin, Brandon Zhou +9 more

Modulation of HER2 internalization enhances single-dose antibody-drug potency in HER2+ gastric cancer

Scientific Reports(2025)10.1038/s41598-025-01947-7
N/A
0DataRank · unranked
2 citations

Alex Benton, Emma Brown, Shayla Shmuel, Alex Vanover, Sandeep Surendra Panikar +5 more